Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands

International Journal of Colorectal Disease

Volumn 29, Issue 10, 2014, Pages 1203-1210

  Stein, Dara ^a   Joulain, F ^b   Naoshy, S ^c   Iqbal, U ^c   Muszbek, N ^d   Payne, K A ^a   Ferry, D ^e   Goey, S H ^f  

^a UNITED BIOSOURCE CORPORATION   (Canada)

^b SANOFI   (France)

^c SANOFI   (United States)

^d EVIDERA   (United Kingdom)

^e RUSSELLS HALL HOSPITAL   (United Kingdom)

^f CPRLab   (Netherlands)

Author keywords

Colorectal cancer; EQ 5D; Health related quality of life; Oncology; Retrospective chart review; Utilities

Indexed keywords

ANTINEOPLASTIC AGENT; OXALIPLATIN; PLATINUM COMPLEX;

ANXIETY; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE COURSE; FEMALE; HUMAN; MALE; MIDDLE AGED; NETHERLANDS; PAIN; PALLIATIVE THERAPY; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; SECONDARY; UNITED KINGDOM;

ACTIVITIES OF DAILY LIVING; ANTINEOPLASTIC AGENTS; ANXIETY; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; DEPRESSION; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; ORGANOPLATINUM COMPOUNDS; PAIN; PALLIATIVE CARE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84929130243     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-014-1980-1     Document Type: Article

References (20)

1. Van Cutsem E, Nordlinger E, Cedrvantes A (2010) Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 21(suppl 5):v93–v97
2. Gallagher DJ, Kemeny N (2010) Metastatic colorectal cancer: from improved survival to potential cure. Oncology 78(3–4):237–248
3. Adam R, Haller DG, Poston G et al (2010) Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer—an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol 21:1579–1584
4. Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26(33):5326–5334
5. National Institute for Health and Clinical Excellence (NICE) (2013) Guide to the methods of technology appraisal. Available at http://publications.nice.org.uk/pmg9
6. The EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16(3):199–208
7. Kind P (1996) The EuroQol instrument: an index of health-related quality of life. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Lippincott-Raven Publishers, Philadelphia, pp 191–201
8. Tappenden P, Jones R, Paisley S, Carroll C (2007) Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 11(12):1–128
9. Hind D, Tappenden P, Tumur I et al (2008) The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 12(15):1–182
10. Bennett L, Zhao Z, Barber B et al (2011) Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. Br J Cancer 105(10):1495–1502
11. Odom D, Barber B, Bennett L et al (2011) Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int J Color Dis 26(2):173–181
12. Starling N, Tilden D, White J, Cunningham D (2007) Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 96(2):206–212
13. Corrie P, The MABEL study (2005) In Roche Submission to the National Institute for Health and Clinical Excellence (NICE): Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer. An open, uncontrolled, multicentre, phase II study of Erbitux (cetuximab) in combination with irinotecan in patients with metastatic colorectal carcinoma expressing the epidermal growth factor receptor and having progressed on a defined irinotecan-based regimen as most recent treatment 2005. Available at http://www.nice.org.uk/nicemedia/live/12098/46368/46368.pdf. Submitted on July 23, 2009
14. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655
15. Cancer therapy evaluation program, common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003 (http://ctep.cancer.gov), Publish date: August 9, 2006
16. MVH Group (1995) The measurement and valuation of health. Final report on the modeling of valuation tariffs. York Centre for Health Economics
17. Best JH, Garrison LP, Hollingworth W, Ramsey SD et al (2010) Preference values associated with stage III colon cancer and adjuvant chemotherapy. Qual Life Res 19(3):391–400
18. Shiroiwa T, Fukuda T, Tsutani K (2009) Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br J Cancer 101(1):12–18
19. Muszbek N, Benedict A, Hortobagyi L (2013) Quality of the end of life—utility values in advanced solid tumors in technology appraisals in the UK. European CanCer Organisation (ECCO) Congress 2013. 27 September–1 October 2013; Amsterdam, Netherlands
20. Batty AJ, Pennington B, Lebmeier M et al (2012) A comparison of patient and general-population utility values for advanced melanoma in health economic modeling. ISPOR 15th Annual European Congress. 3–10 November, 2012. Berlin, Germany